Related Experiment Video
Updated: Mar 9, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Disruption of the microbiota across multiple body sites in critically ill children
Matthew B Rogers1, Brian Firek1, Min Shi2
1Department of Surgery, School of Medicine, University of Pittsburgh, Pittsburgh, USA.
Insights
Critically ill children in the pediatric intensive care unit (PICU) exhibit significant gut microbiome dysbiosis, with reduced diversity and altered microbial composition compared to healthy individuals. This dysbiosis may present opportunities for targeted therapeutic interventions.
Area of Science:
- Microbiology
- Human Health
- Critical Care Medicine
Background:
- The human microbiome's role in health is increasingly recognized, yet its state in pediatric intensive care unit (PICU) patients remains understudied.
- Dysbiosis, an imbalance in microbial communities, is a potential concern for critically ill populations.
Purpose of the Study:
- To characterize the microbial diversity and composition in children admitted to a PICU.
- To compare the PICU microbiota with healthy adult and pediatric reference datasets.
Main Methods:
- Analysis of bacterial 16S rRNA gene sequences from tongue, skin, and stool/rectal samples of 37 PICU children.
- Calculation of alpha and beta diversity metrics.
- Comparison with existing adult and pediatric microbiome data.
Main Results:
- PICU patients showed decreased alpha diversity in gut and tongue samples compared to healthy controls.
- Beta diversity analysis revealed distinct microbial community structures in PICU patients across body sites.
- Enrichment of pathogens like Enterococcus and Staphylococcus, and depletion of commensals like Faecalibacterium and Ruminococcus were observed.
- Microbiota composition was unstable over time and exhibited a loss of site specificity.
- Dominant pathogens (>50% relative abundance) were frequently detected.
Conclusions:
- The gut microbiota of critically ill children in the PICU is significantly altered compared to healthy children and adults.
- Recognizing this dysbiosis offers potential avenues for precise microbiota modulation to improve patient outcomes.
Background:
Despite intense interest in the links between the microbiome and human health, little has been written about dysbiosis among ICU patients. We characterized microbial diversity in samples from 37 children in a pediatric ICU (PICU). Standard measures of alpha and beta diversity were calculated, and results were compared with data from adult and pediatric reference datasets.
Results:
Bacterial 16S rRNA gene sequences were analyzed from 71 total tongue swabs, 50 skin swabs, and 77 stool samples or rectal swabs. The mean age of the PICU patients was 2.9 years (range 1-9 years), and many were chronically ill children that had previously been hospitalized in the PICU. Relative to healthy adults and children, alpha diversity was decreased in PICU GI and tongue but not skin samples. Measures of beta diversity indicated differences in community membership at each body site between PICU, adult, and pediatric groups. Taxonomic alterations in the PICU included enrichment of gut pathogens such as Enterococcus and Staphylococcus at multiple body sites and depletion of commensals such as Faecalibacterium and Ruminococcus from GI samples. Alpha and beta diversity were unstable over time in patients followed longitudinally. We observed the frequent presence of "dominant" pathogens in PICU samples at relative abundance >50%. PICU samples were characterized by loss of site specificity, with individual taxa commonly present simultaneously at three sample sites on a single individual. Some pathogens identified by culture of tracheal aspirates were commonly observed in skin samples from the same patient.
Conclusions:
We conclude that the microbiota in critically ill children differs sharply from the microbiota of healthy children and adults. Acknowledgement of dysbiosis associated with critical illness could provide opportunities to modulate the microbiota with precision and thereby improve patient outcomes.

